<DOC>
	<DOCNO>NCT00640276</DOCNO>
	<brief_summary>We identify influence long-term treatment Pitavastatin compare non-treatment control group metabolic syndrome evaluation change metabolic syndrome component score . And additionally observe change CVD risk factor like lipid profile , abdominal fat , insulin resistance .</brief_summary>
	<brief_title>Safety Efficacy Study Pitavastatin Patient With Metabolic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Pitavastatin</mesh_term>
	<criteria>Patients age 18 75 Patients LDL ≥ 100mg/dL Patients metabolic syndrome 1 . IFG : Fasting glucose ≥ 100mg/dL 2 . Abdominal Obesity : Waist circumference : men≥90cm , women≥85cm 3 . 1 follow 1 . Triglyceride ≥ 150mg/dL 2 . HDLC : men &lt; 40mg/dL , woman &lt; 50mg/dL 3 . Blood pressure : SBP ≥ 130mmHg DBP ≥ 85mmHg subject receive antihypertensive treatment uncontrolled hypertension ( DBP ≥ 95mmHg ) take diabetic drug HbA1c &gt; 8 % LDL ≥ 190mg/dL Triglyceride ≥ 400mg/dL coronary heart disease disease cause artherosclerosis malignancy within 6 month Serum creatinine ≥ 2.0mg/dL ALT AST ≥ ULN*2.5 CPK ≥ ULN*2 hypothyroidism</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>pitavastatin</keyword>
	<keyword>metabolic syndrome</keyword>
	<keyword>metabolic syndrome risk score</keyword>
	<keyword>hypercholesterolemia</keyword>
</DOC>